---
title: "Hong Kong's Hidden Gems Break Out: FDA Approvals and Louvre Stores Fuel Growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300409668.md"
description: "Alebund (9637.HK) secured FDA approval for its groundbreaking IgA therapy while CHABAIDAO (2555.HK) opened at Louvre, signaling how Hong Kong's small-caps leverage global validation over scale. Fosun Pharma (2196.HK) and AGTech (8279.HK) executed precision partnerships, with select stocks gaining over 10% weekly despite broader market weakness."
datetime: "2026-09-29T09:16:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300409668.md)
  - [en](https://longbridge.com/en/news/300409668.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300409668.md)
generator: "portal-rs"
---

# Hong Kong's Hidden Gems Break Out: FDA Approvals and Louvre Stores Fuel Growth

Hong Kong's overlooked small-caps are rewriting growth playbooks through targeted global partnerships. Alebund Pharmaceuticals (9637.HK) made history as its AP308 became the first IgA nephropathy enzyme therapy cleared by the FDA, triggering a 17% single-day surge. CHABAIDAO (2555.HK) turned the Louvre's Carrousel 商场 into a strategic beachhead, with 130+ overseas stores now secured across 13 markets. Fosun Pharma (2196.HK) activated its T-MATE™ platform via Amberstone collaboration, while AGTech (8279.HK) embedded Ant Group's AI payment protocol into Macau's MPay system.

Industrial innovators are equally strategic: Harbin Electric (6915.HK) acquired marine drone capabilities through a 17.27 million HKD deal, and CNGR Advanced Material (2579.HK) positioned itself for solid-state battery commercialization ahead of 2027 policy milestones. Even Shouhui Group (2621.HK), dismissed as "marginal" by analysts, reported dual revenue-profit growth amid insurtech headwinds. The common thread? Precision internationalization over brute-force expansion – where Louvre storefronts and FDA approvals matter more than pure scale.

### Related Stocks

- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [08279.HK](https://longbridge.com/en/quote/08279.HK.md)
- [09637.HK](https://longbridge.com/en/quote/09637.HK.md)
- [02621.HK](https://longbridge.com/en/quote/02621.HK.md)
- [06700.HK](https://longbridge.com/en/quote/06700.HK.md)
- [02313.HK](https://longbridge.com/en/quote/02313.HK.md)
- [06915.HK](https://longbridge.com/en/quote/06915.HK.md)
- [02579.HK](https://longbridge.com/en/quote/02579.HK.md)
- [02555.HK](https://longbridge.com/en/quote/02555.HK.md)
- [01133.HK](https://longbridge.com/en/quote/01133.HK.md)

## Related News & Research

- [Shanghai Fosun Pharmaceutical Files HKEX Return Disclosing Share Buyback](https://longbridge.com/en/news/305947957.md)
- [Shanghai Fosun Pharma Files HKEX Next-Day Return Disclosing Share Buyback](https://longbridge.com/en/news/306090882.md)
- [Fosun Pharma Starts Phase II Trial of FXR0906 for Hypertriglyceridemia in China](https://longbridge.com/en/news/305650774.md)
- [Alebund Pharmaceuticals Files HKEX Next-Day Disclosure Return on Share Buyback](https://longbridge.com/en/news/305988477.md)
- [Fosun Subsidiary Receives Clinical-Trial Approval for FAP PET Drug](https://longbridge.com/en/news/305658233.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**